Experimental combo aims to tackle advanced liver cancer
NCT ID NCT07540832
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called WGI-0301 combined with lenvatinib in 80 people with advanced liver cancer who have already tried one treatment. The goal is to see if the combination is safe, tolerable, and shrinks tumors. It is an open-label, non-placebo trial across several hospitals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- WGI-0301 (an experimental drug) plus lenvatinib (a targeted therapy)
- What this could lead to
- If it works, this combination could offer a new second-line treatment option for people with advanced liver cancer who have not responded to first-line therapy.
- What could go wrong
- This is an early-phase trial with only 80 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo aims to outperform standard care in advanced liver cancer
- Immunotherapy combo aims to shrink advanced liver tumors
- New study aims to find best first immunotherapy for advanced liver cancer
- New immunotherapy combo takes on advanced liver cancer
- Engineered immune cells take on Hard-to-Treat liver cancer
- Supercharged immune cells take on advanced liver cancer